Continued Increase of Erythromycin Nonsusceptibility and Clindamycin Nonsusceptibility Among Invasive Group A Streptococci Driven by Genomic Clusters, United States, 2018-2019

Clin Infect Dis. 2023 Feb 8;76(3):e1266-e1269. doi: 10.1093/cid/ciac468.

Abstract

We analyzed 9630 invasive GAS surveillance isolates in the USA. From 2015-2017 to 2018-2019, significant increases in erythromycin-nonsusceptibility (18% vs 25%) and clindamycin-nonsusceptibility (17% vs 24%) occurred, driven by rapid expansions of genomic subclones. Prevention and control of clustered infections appear key to containing antimicrobial resistance.

Keywords: antimicrobial resistance; genomic cluster; group A Streptococcus; invasive disease.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Clindamycin* / pharmacology
  • Drug Resistance, Bacterial / genetics
  • Erythromycin / pharmacology
  • Genomics
  • Humans
  • Microbial Sensitivity Tests
  • Streptococcal Infections* / drug therapy
  • Streptococcal Infections* / epidemiology
  • Streptococcus pyogenes / genetics
  • United States / epidemiology

Substances

  • Clindamycin
  • Erythromycin
  • Anti-Bacterial Agents